Dr Richard Hopkins Appointed as CEO of PharmAust
Filed with ASX · · 3 pages · English
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- Appendix 4D & Financial Report - Dec 2016
- Appendix 4C - Quarterly Report & Company Update
- PharmAust Receives $406K R&D Rebate from ATO
- Phase II Strategy Update
- Phase II Canine Trial begins at University of Cambridge
Later from Neurizon Therapeutics
- Appendix 4C - Quarterly Report & Company Update - March 2017
- PharmAust secures core China patent
- New patent granted for non-cancer applications
- Phase II trial prelim results demonstrate clinical benefit
- PharmAust secures core patent in Japan
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics